Actas urologicas espanolas最新文献

{"title":"Comment to: «Association between varicocele and hypogonadism, or erectile dysfunction: A systematic review and meta-analysis»","authors":"N. Razaqi , R. Mehta , S. Kumar , R. Sah","doi":"10.1016/j.acuroe.2025.501743","DOIUrl":"10.1016/j.acuroe.2025.501743","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 5","pages":"Article 501743"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota and prostate cancer: An analysis of bacterial communities across various clinical scenarios","authors":"M. Carballo Quintá ,&nbsp;S. Perez Castro ,&nbsp;A. Freire Rodriguez ,&nbsp;C. Daviña Nuñez ,&nbsp;A. Bellas Pereira ,&nbsp;J.J. Cabrera Alvargonzalez ,&nbsp;M. Perez Schoch ,&nbsp;C.A. Muller Arteaga ,&nbsp;J.F. Sanchez Garcia ,&nbsp;E. Cespón Outeda ,&nbsp;E. Lopez Diez","doi":"10.1016/j.acuroe.2025.501748","DOIUrl":"10.1016/j.acuroe.2025.501748","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Gut microbiota (GM) comprises a diverse community of bacteria associated with a wide range of diseases. Emerging research indicates that GM dysbiosis may affect the progression of prostate cancer (PC) and its response to treatment. This study aimed to describe GM in patients with PC at various disease stages.</div></div><div><h3>Materials and methods</h3><div>A cross-sectional study was conducted at Complejo Hospitalario Universitario de Vigo between 2023 and 2024. 49 patientes were classified into three groups: active surveillance (AS), disease-free post-treatment (DF) and advanced disease (AD). Faecal samples were obtained for GM analysis and DNA was used for 16S rRNA sequencing. The structure of the microbial community was examined via alpha and beta diversity analysis, and differential abundance was measured using the LinDA model.</div></div><div><h3>Results</h3><div>Alpha diversity analysis revealed diminished taxon richness in patients under AS and in those treated with androgen receptor pathway in hibitors (ARPI). Beta diversity analysis indicated substantial changes attributable to the treatment group, radiation, hormone therapy, and ARPI. The AD group had a diminished number of potentially advantageous bacteria (<em>Methanobrevibacter</em>, <em>Paraprevotella</em>, <em>Colidextribacter</em>) and an elevated abundance of Terrisporobacter and Streptococcus compared to the DF group. The AS group showed reduction in <em>Intestinibacter</em>, <em>Adlercreutzia</em>, <em>Subdoligranulum</em>, and <em>Methanobrevibacter</em>, along with an increase in <em>Fusicatenibacter</em>, <em>Lachnospiraceae</em>, and <em>Lachnoclostridium</em>.</div></div><div><h3>Conclusions</h3><div>Patients who remain disease-free after therapy have restored microbiota abundant in potential beneficial bacteria, in contrast to individuals with severe disease or those under active monitoring. This study indicates that gut microbiome characteristics could assist in risk assessment and act as possible treatment targets for prostate cancer.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 5","pages":"Article 501748"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author’s response to the comment regarding the methodological aspects of «Association between varicocele and hypogonadism, or erectile dysfunction: A systematic review and meta-analysis»","authors":"H.A. García-Perdomo","doi":"10.1016/j.acuroe.2025.501754","DOIUrl":"10.1016/j.acuroe.2025.501754","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 5","pages":"Article 501754"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of a multidisciplinary approach on treatment decisions and outcomes in urothelial carcinoma: A systematic review","authors":"E. Albers Acosta ,&nbsp;L. Pelari-Mici ,&nbsp;G. Celada Luis ,&nbsp;C. Velasco Balanza ,&nbsp;A. Zapatero ,&nbsp;N. Romero-Laorden ,&nbsp;P. Toquero Diez ,&nbsp;J. Caño-Velasco ,&nbsp;F. Guerrero-Ramos ,&nbsp;M. Moschini ,&nbsp;W. Krajewski ,&nbsp;F. Del Giudice ,&nbsp;F. Soria ,&nbsp;E. Laukhtina ,&nbsp;L. Mertens ,&nbsp;R. Pichler ,&nbsp;K. Mori ,&nbsp;D. D’Andrea ,&nbsp;A. Mari ,&nbsp;G. Marcq ,&nbsp;L. San José Manso","doi":"10.1016/j.acuroe.2025.501718","DOIUrl":"10.1016/j.acuroe.2025.501718","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Urothelial carcinoma is a challenging disease that requires a comprehensive approach. Multidisciplinary tumor committees are essential to bring specialists together, optimize treatment, ensure individualized care, and promote evidence-based decision making. This study aims to collect evidence and explore the impact of multidisciplinary tumor committees in the management of urothelial carcinoma.</div></div><div><h3>Materials and methods</h3><div>A systematic review was performed following PRISMA guidelines. We searched PubMed/Medline, Embase, Scopus and Cochrane databases for relevant studies on the role of multidisciplinary committees in the management of urothelial carcinoma, including bladder cancer, upper tract urothelial carcinoma and urethral carcinoma. Given the limited and heterogeneous evidence, a systematic review with narrative synthesis was performed.</div></div><div><h3>Results</h3><div>Multidisciplinary tumor committees had a significant impact on the diagnosis and treatment of urothelial neoplasms, especially bladder cancer. Consistent findings showed that these committees produced substantial changes in treatment, improved adherence to clinical guidelines, and demonstrated a potential to improve patient outcomes. In addition, multidisciplinary committees increased the likelihood of curative treatments and were associated with reduced mortality rates, enhanced clinical decision making, and improved patient care, particularly in bladder and upper tract urothelial carcinoma.</div></div><div><h3>Conclusions</h3><div>This review highlights the essential role of multidisciplinary tumor committees in improving the management of urothelial carcinoma of the bladder and upper urinary tract. However, further research using standardized approaches is needed. The absence of studies on urethral carcinoma underlines the urgent need to investigate the potential benefits of multidisciplinary tumor committees. Future studies should cover a wider range of tumor types and follow standardized methodologies to provide a more complete and generalizable picture.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 5","pages":"Article 501718"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robot-assisted transmesocolic retroperitoneal lymphadenectomy in testicular non-seminomatous germ cell tumors: A promising approach","authors":"J. Palou,&nbsp;M. Casadevall,&nbsp;O. Rodríguez Faba,&nbsp;J.M. Gaya,&nbsp;A. Breda","doi":"10.1016/j.acuroe.2025.501687","DOIUrl":"10.1016/j.acuroe.2025.501687","url":null,"abstract":"<div><h3>Introduction</h3><div>Testicular cancer accounts for 5% of urological tumors, with an incidence of 5.6 cases per 100,000 men per year in Europe (1). Salvage retroperitoneal lymphadenectomy is the standard surgery for persistent retroperitoneal masses after chemotherapy. The advent of minimally invasive surgery is changing the therapeutic approach. The objective is to present our initial experience with the transmesocolic robotic approach for the surgical management of these masses.</div></div><div><h3>Methods</h3><div>We report the perioperative and oncological outcomes of four patients affected by non-seminomatous germ cell tumors who were treated with transmesocolic robotic left para-aortic retroperitoneal lymphadenectomy.</div></div><div><h3>Results</h3><div>The surgical time for the first case was 220 min, and the average surgical time for the remaining cases was 120 min (SD: 15). Estimated blood loss was 82.5 mL (SD: 79.3). No intraoperative or postoperative complications were observed. Pathological anatomy revealed post-pubertal teratoma (30%) and necrosis (70%) in case 1, necrosis with reactive adenitis in case 2, extensive fibrosis in case 3 and post-pubertal teratoma in case 4. Currently, all patients are disease-free.</div></div><div><h3>Conclusions</h3><div>Robotic retroperitoneal lymphadenectomy is a safe and precise technique that offers favorable oncological and functional outcomes. The transmesocolic approach represents a feasible option in selected cases, ensuring rapid retroperitoneal access and reduced surgical time.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 5","pages":"Article 501687"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiofrequency induced hyperthermia in non-muscle invasive bladder cancer: Oncologic outcomes in a real-world scenario","authors":"S. Mero ,&nbsp;K. Oberneder ,&nbsp;J. Weiss ,&nbsp;E. Grobet-Jeandin ,&nbsp;A. Grégoris ,&nbsp;P. Sèbe ,&nbsp;S. Shariat ,&nbsp;D. D’Andrea","doi":"10.1016/j.acuroe.2025.501746","DOIUrl":"10.1016/j.acuroe.2025.501746","url":null,"abstract":"<div><h3>Objectives</h3><div>Patients with non-muscle invasive bladder cancer (NMIBC) face a high risk of recurrence and progression after transurethral resection, making adjuvant therapies necessary. Intravesical device-assisted therapies, such as radiofrequency-induced thermochemotherapy (RITE), have shown promise in enhancing the effectiveness of intravesical chemotherapies. This study aimed to evaluate oncological outcomes in patients with NMIBC treated with RITE in a real-world setting, encompassing those unresponsive to prior Bacillus Calmette-Guérin (BCG) or intravesical chemotherapy, as well as those who declined or were ineligible for BCG or radical cystectomy (RC).</div></div><div><h3>Methods</h3><div>A retrospective multicenter analysis of patients treated with RITE for NMIBC between 2015 and 2024 was performed. Co-primary endpoints of the study were intravesical recurrence free survival (RFS) and high-grade intravesical recurrence free survival (HG-RFS). Secondary endpoints included radical cystectomy-free survival (RC-FS), overall survival (OS), cancer-specific survival (CSS), and adverse events (AEs).</div></div><div><h3>Results</h3><div>Fifty-nine consecutive patients were included in the final analyses. Overall, 12 (20%) and 45 (76%) patients failed previous intravesical chemotherapy, and immunotherapy with BCG, respectively. The 24-months RFS and HG-RFS following RITE were 68.6% (95% CI: 0.568, 0.828) and 74.8% (95% CI: 0.632, 0.885). RC-FS at 24 months was 93.8% (95% CI: 0.872, 1.000). The OS probability at 24 months was 91%, with a CSS of 97.8%. Most common AEs were dysuria and urgency in 27 (45.7%) patients, treatment limiting bladder spasms in 11 (19%) patients, low bladder compliance in 11 (19%) patients and urethral strictures in 5 (8%) patients.</div></div><div><h3>Conclusion</h3><div>In our analyses, RITE resulted in notable antitumor activity and allows for the avoidance of more aggressive and quality-of-life-limiting therapies, such as radical cystectomy. RITE might be considered as a second-line bladder-sparing option in patients failing previous intravesical therapies. Long-term follow-up and larger-scale data are required to validate our findings.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 5","pages":"Article 501746"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Novel risk factors for Venous Thromboembolism (VTE) following outpatient or inpatient Transurethral Resection of Bladder Tumors (TURBT): Multivariable Stepwise and LASSO Regression Modeling from US Insurance Claim database\".","authors":"S Kumar, R Mehta, R Sah","doi":"10.1016/j.acuroe.2025.501787","DOIUrl":"10.1016/j.acuroe.2025.501787","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":"501787"},"PeriodicalIF":0.0,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144145370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of HCY, sdLDL-C, Crea, inflammatory factor IL-6 and prostate-specific antigen in the diagnosis of benign prostatic hyperplasia in the elderly","authors":"W. Qin,&nbsp;S. Liu,&nbsp;L. Liu,&nbsp;M. Liu,&nbsp;J. Chen,&nbsp;P. Dai","doi":"10.1016/j.acuroe.2025.501744","DOIUrl":"10.1016/j.acuroe.2025.501744","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the diagnostic value of serum metabolic markers such as HCY, sdLDL-C, Crea, inflammatory factor IL-6 and prostate-specific antigen in elderly patients with prostatic hyperplasia (BPH).</div></div><div><h3>Methods</h3><div>150 senile patients with hyperplasia of prostate were selected as observation group and 169 healthy senile patients were selected as control group. The tPSA, fPSA, fPSA/t PSA and prostate size data of the two groups were collected, and serum samples of the subjects were collected for the detection of HCY, sdLDL, Crea, IL-6 and other indicators. Univariate analysis, correlation analysis and Logistic regression analysis were conducted to analyze the relationship between each index and senility prostatic hyperplasia. The diagnostic efficiency of each serum metabolite was analyzed by receiver operating characteristic curve (ROC).</div></div><div><h3>Results</h3><div>Serum levels of tPSA, fPSA, Crea, HCY, sdLDL-C and IL-6 were significantly increased, fPSA/tPSA ratio and HDL were significantly decreased, and TCHO, TG and LDL had no statistical significance. Serum tPSA and fPSA levels were positively correlated with prostate size, serum IL-6, Crea and HCY levels were positively correlated with tPSA and fPSA levels, and serum sdLDL-C levels were negatively correlated with fPSA levels. Logistic regression analysis showed that tPSA, fPSA, prostate size, HCY, Crea and IL-6 were risk factors for prostate hyperplasia. HDL and fPSA/tPSA are protective factors for benign prostatic hyperplasia. ROC curve analysis showed that the sensitivity and specificity of fPSA/tPSA and IL-6 were 82.7% and 72%, 83.4% and 80.5%, and the area under ROC curve were 0.840 and 0.825, respectively. tPSA and fPSA combined with HCY, IL-6 and Crea had the best diagnostic efficiency, with the area under ROC curve reaching 0.881, specificity and sensitivity reaching 84% and 77.3%, respectively.</div></div><div><h3>Conclusion</h3><div>The combined detection of prostate-specific antigen, HCY, Crea and IL-6 can significantly improve the diagnostic efficiency of senile prostatic hyperplasia, and optimize the diagnosis and treatment scheme can even be used as a major screening index to evaluate and predict the incidence of BPH in senile prostatic hyperplasia.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 4","pages":"Article 501744"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143653069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial clinical experience with Zr-Girentuximab PET-CT for the evaluation of renal masses in patients with solitary kidneys","authors":"D.A. González-Padilla ,&nbsp;D. Sánchez Zalabardo ,&nbsp;E.F. Guillén-Valderrama ,&nbsp;F. Villacampa-Aubá","doi":"10.1016/j.acuroe.2025.501691","DOIUrl":"10.1016/j.acuroe.2025.501691","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 4","pages":"Article 501691"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter study of the impact of Urolift® implantation in patients undergoing medical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia","authors":"C. González Enguita ,&nbsp;L. López Martín ,&nbsp;L.M. Herranz Fernández ,&nbsp;B. Sinues Ojas ,&nbsp;C. Barrera Rodríguez ,&nbsp;J. Extramiana Cameno ,&nbsp;J. Campá Bortoló ,&nbsp;J.M. Oscá García ,&nbsp;M. Perán Teruel ,&nbsp;V. Gimeno Argente ,&nbsp;A. Navarro Beltrán ,&nbsp;E. López Alcina ,&nbsp;I. Povo Martín ,&nbsp;Y. Salvador Pallás Costa ,&nbsp;A. Budía Alba ,&nbsp;J. Ortiz Salvador ,&nbsp;J.J. Salgado Plonski ,&nbsp;P. Suárez Sal ,&nbsp;M. Fernández Arjona","doi":"10.1016/j.acuroe.2025.501708","DOIUrl":"10.1016/j.acuroe.2025.501708","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>UroLift® is a minimally invasive treatment for patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. The primary objective was to evaluate the impact of UroLift® system treatment on quality of life. Secondary objectives assessed the impact on urinary symptoms and sexual function.</div></div><div><h3>Patients and methods</h3><div>Patients at 7 Spanish hospitals undergoing pharmacological treatment were offered the choice to continue this treatment or accept surgical intervention. The primary outcome, impact on quality of life, was assessed using the EuroQol-5D-5L questionnaire. Secondary outcomes, including impact on symptoms, erectile function, and ejaculatory function, were evaluated using the IPSS, SHIM-5, and MSHQ-EjD-SF questionnaires, respectively. Outcomes were compared between groups.</div></div><div><h3>Results</h3><div>91 patients chose UroLift® and 45 continued with pharmacotherapy. At 6 months, a positive impact on quality of life was estimated with UroLift® (0.046; SD: 0.02; p = 0.067), being significant in subgroups of patients aged &gt;65 years (diff.: 0.034), PSA &gt; 2.2 (diff.: 0.108), diabetes mellitus (diff.: 0.023), hypertension (diff.: 0.011) or hypercholesterolemia (diff.: 0.016). The impact on symptomatology was superior with UroLift® (−10.07; SD: 1.65; p &lt; 0.001), being significant in subgroups aged &gt;65 (diff.: 1.37), prostate &gt;40 cc (diff.: 0.74), PSA &gt; 2.2 (diff.: 2.63), and diabetes mellitus (diff.: 1.66), hypertension (diff.: 1.23). Erectile function was not affected (-0.33; SD: 1.99; p = 0.868) while ejaculatory function showed a favorable impact (2.98; SD: 1.26; p = 0.019).</div></div><div><h3>Conclusions</h3><div>Minimally invasive Urolift® system treatment is associated with a positive impact on quality of life and urinary symptoms without adversely affecting sexual function.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"49 4","pages":"Article 501708"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}